Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
Earnings Data
Report Date
Mar 04, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.34Last Year’s EPS
-0.88Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted a successful launch and positive market reception of PALSONIFY, which is expected to drive substantial growth. However, delays in the Graves' disease candidate and the SST3 agonist program were noted. Overall, the sentiment is positive given the successful launch and financial stability.Company Guidance
Successful Launch of PALSONIFY
The launch of PALSONIFY is proceeding well, with 95% of prescriptions filled by switch patients and some naive patients starting on therapy. The company plans to make PALSONIFY the first-line treatment for acromegaly.
Positive Reception from Healthcare Providers
PALSONIFY has been well received by both academic and community physicians. 95% of top priority prescribers have been contacted, with 70% of prescribers coming from the community setting.
Favorable Payer Feedback
Payers have been receptive to PALSONIFY, with prior authorizations being straightforward and some approvals for up to 12-month supplies. Coverage approvals are coming across commercial, Medicare, and Medicaid plans.
Strong Financial Position
Crinetics ended the quarter with $1.1 billion in cash, with guidance that existing cash and investments will be sufficient to fund operations into 2029.
CRNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $43.49 | $40.00 | -8.02% |
Aug 07, 2025 | $27.88 | $26.85 | -3.69% |
May 08, 2025 | $32.70 | $30.68 | -6.18% |
Feb 27, 2025 | $33.21 | $35.78 | +7.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Crinetics Pharmaceuticals (CRNX) report earnings?
Crinetics Pharmaceuticals (CRNX) is schdueled to report earning on Mar 04, 2026, TBA (Confirmed).
What is Crinetics Pharmaceuticals (CRNX) earnings time?
Crinetics Pharmaceuticals (CRNX) earnings time is at Mar 04, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRNX EPS forecast?
CRNX EPS forecast for the fiscal quarter 2025 (Q4) is -1.34.